Quantcast

Latest Orphan receptor Stories

2013-08-30 23:18:32

GPCR Screening and Profiling Trends 2013 (http://www.reportsnreports.com/reports/267694-gpcr-screening-profiling-trends-2013.html) report survey looked at both in house and outsourced GPCR primary screening and compound profiling. Dallas, Texas (PRWEB) August 30, 2013 This market report summarizes the results of industry-wide global web-based benchmarking survey on GPCR screening and profiling carried out in August 2013. The survey was initiated by HTStec as part of its tracking of life...

2011-05-31 06:00:00

SEATTLE, May 31, 2011 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today reported that it has identified compounds that interact with orphan G protein-coupled receptors (GPCRs) GPR27 and GPR173. These receptors, together with GPR85, an orphan GPCR that Omeros previously unlocked, form the SREB (Super Conserved Receptor Expressed in Brain) family, a unique and evolutionarily conserved family of orphan GPCRs thought to be critical in regulating neural integrity. The SREB family is...

2011-03-02 06:00:00

SEATTLE, March 2, 2011 /PRNewswire/ -- Omeros Corporation (Nasdaq: OMER) today announced that it has identified compounds that interact selectively with two orphan G protein-coupled receptors (GPCRs) linked to pancreatic cancer (GPR182) and cognitive disorders (GPR12). Together with the three previously unlocked orphans linked to squamous cell carcinoma (GPR87), obesity (GPR85) and appetite control (GPR101), Omeros has now successfully unlocked five orphan GPCRs. GPCRs represent the...

2010-11-09 06:00:00

SEATTLE, Nov. 9, 2010 /PRNewswire/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that a compound identified by the Company as an antagonist of GPR87, an orphan GPCR recently unlocked for drug development by Omeros and linked to squamous cell carcinoma, potentiates the tumor-killing activity of doxorubicin (Adriamycin), a...

2010-10-25 02:50:00

SEATTLE, Oct. 25 /PRNewswire-FirstCall/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that it has received $20 million from Vulcan Capital (Vulcan) and a grant award for $5 million from Washington State's Life Sciences Discovery Fund (LSDF) to support the advancement of the Company's G protein-coupled receptor (GPCR)...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related